Free Trial
→ Why More Investors Are Using Family Trusts to Protect Their Wealth (From SmartAsset) (Ad)tc pixel

Chris Schott Analyst Performance

Analyst at JPMorgan Chase & Co.

Chris Schott is a stock analyst at JPMorgan Chase & Co. in the medical sector, covering 24 publicly traded companies. Over the past year, Chris Schott has issued 13 stock ratings, including buy and hold recommendations. While full access to Chris Schott's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Chris Schott's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Analyst Ranking
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
113 Last 10 Years
Buy Recommendations
70.48% 74 Buy Ratings
Companies Covered
24 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy70.5%74 ratings
Hold27.6%29 ratings
Sell1.9%2 ratings

Out of 105 total stock ratings issued by Chris Schott at JPMorgan Chase & Co., the majority (70.5%) have been Buy recommendations, followed by 27.6% Hold and 1.9% Sell.

Best & Worst Calls

Exchange Coverage

ExchangePercentageCount
NASDAQ
54.2% of companies on NASDAQ
13 companies
NYSE
45.8% of companies on NYSE
11 companies

Chris Schott, an analyst at JPMorgan Chase & Co., currently covers 24 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
24 companies		100.0%

Chris Schott of JPMorgan Chase & Co. specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
7 companies		29.2%
PHARMACEUTICAL PREPARATIONS
5 companies		20.8%
LARGE CAP PHARMA
4 companies		16.7%
MED - DRUGS
3 companies		12.5%
MED - GENERIC DRG
2 companies		8.3%
MED PRODUCTS
1 company		4.2%
MED INSTRUMENTS
1 company		4.2%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC
1 company		4.2%

Chris Schott's Ratings History at JPMorgan Chase & Co.

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
Export to Excel
CompanyReport DateActionReport Date Price12-Month
Price Target		Rating12-Month
Price & ROI		Details
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
9/16/2025Boost Price Target$112.54$145.00Overweight
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
9/16/2025Lower Price Target$748.26$1,050.00Overweight
AMNEAL PHARMACEUTICALS, INC. stock logo
AMRX
AMNEAL PHARMACEUTICALS
9/16/2025Boost Price Target$9.79$14.00Overweight
AbbVie Inc. stock logo
ABBV
AbbVie
9/16/2025Boost Price Target$217.92$235.00Overweight
Perrigo Company plc stock logo
PRGO
Perrigo
8/7/2025Lower Price Target$22.83$35.00Overweight
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
8/4/2025Boost Price Target$682.78$675.00Overweight
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
6/9/2025Lower Price Target$502.10$800.00Overweight
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
5/12/2025Upgrade$16.94$23.00Overweight
Biogen Inc. stock logo
BIIB
Biogen
5/5/2025Lower Price Target$123.14$175.00Neutral
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
3/31/2025Lower Price Target$634.04$1,000.00Overweight
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
3/27/2025Boost Price Target$111.01$130.00Overweight
AMNEAL PHARMACEUTICALS, INC. stock logo
AMRX
AMNEAL PHARMACEUTICALS
2/24/2025Upgrade$7.83$12.00Overweight
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
1/29/2025Boost Price Target$93.85$115.00Overweight
Today's Ratings
Top-Rated Stocks
More Ratings Tools